Hiv Vaccine Trials Network

What Hiv Vaccine Trials Network does

The HIV Vaccine Trials Network (HVTN) is the world's largest publicly funded collaboration dedicated to evaluating vaccines for the prevention of HIV/AIDS. Founded in 1987 and headquartered at the Fred Hutchinson Cancer Center in Seattle, WA, HVTN operates as a 501(c)(3) non-profit research network funded through cooperative agreements with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The network runs all phases of clinical trials (Phase 1, 2, 2b, and 3) across more than 70 clinical research sites on four continents, with protocols reviewed by the DAIDS Prevention Science Review Committee and the Vaccine Research Program.

HVTN's core product is its clinical trial execution capability, evaluating multiple vaccine platform technologies including protein subunit, nucleic acid (DNA/mRNA), viral vector, virus-like particle, and live-attenuated designs, as well as broadly neutralizing antibodies (bnAbs) through Antibody Mediated Prevention (AMP) studies. Supporting services include the VISP Testing Service for appropriate HIV diagnosis in vaccine recipients, the Bill of Rights and Responsibilities for HIV and Tuberculosis Research, Community Advisory Boards at every site, the Faith Initiative, and the Auxiliary Studies Program that has shared data and specimens with more than 150 collaborating institutions.

HVTN has expanded beyond HIV to include tuberculosis and COVID-19 vaccine research, signaling an intent to serve as an integrated infectious disease vaccine evaluation platform. The organization does not generate commercial revenue: participation is voluntary, the network's funding flows from NIAID/NIH cooperative agreements, and the HVTN's primary customer base consists of healthy HIV-negative adult volunteers, NIAID-selected clinical trial sites and principal investigators, community organizations, and auxiliary research collaborators.

Name

Hiv Vaccine Trials Network

Legal name

HIV Vaccine Trials Network

Website

https://hvtn.org

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

101–250 employees

Short description

The HIV Vaccine Trials Network (HVTN) is a federally funded, Seattle-based non-profit research network that conducts all phases of clinical trials for HIV, tuberculosis, and COVID-19 vaccines across 70+ sites on four continents, serving trial volunteers, NIAID, and the global HIV prevention research community.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

akta.pro secondary industries

Disease-Specific Reference Laboratory Networks (e.g., TB, HIV, Influenza) (HLAJAIAD), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), HIV/AIDS Medicine (HLAKAGAB)

Keywords

• HIV vaccine clinical trials
• Clinical research network
• Vaccine trial coordination
• HIV prevention research
• Immunology clinical studies

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Federal Research Grants and Cooperative Agreements: The HVTN is a publicly funded research network supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) through cooperative agreements. The network does not generate commercial revenue; it operates as a non-profit scientific research collaboration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

The Hiv Vaccine Trials Network (HVTN) is a nonprofit clinical research organization that designs, conducts, and analyzes HIV vaccine clinical trials. It recruits and enrolls study participants, manages trial site operations, and collaborates with research institutions and funding agencies to advance HIV vaccine development.

Product overview

The HIV Vaccine Trials Network (HVTN) is a clinical research organization, not a software product company. Its offerings consist of conducting all phases of clinical trials (Phase 1, 2, 2b, and 3) for HIV vaccines, testing broadly neutralizing antibodies for prevention (AMP studies), tuberculosis vaccine studies, and COVID-19 research. Supporting programs include the VISP Testing Service for appropriate HIV diagnosis in vaccine trial participants, the HVTN Faith Initiative for community outreach, and Community Advisory Boards at each site. Educational and mentorship programs include the Research and Mentorship Program (RAMP) for medical students, Scientific Leadership Development Awards, Scientific Pilot Awards, and the annual Translational HIV Vaccine ESI Conference. The network operates over 70 clinical trial sites across Africa, North America, and Central/South America, supported by auxiliary studies that share data and specimens with collaborating researchers.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 29% increase in visit completions since last reporting period; 110% increase in CRF data pages processed
• +4 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Fred Hutchinson Cancer CentercoreStrategic or Co-development PartnerHVTN is headquartered at Fred Hutchinson Cancer Center in Seattle, WA. Fred Hutch provides institutional infrastructure, administrative support, and is the parent institution. The HVTN coverage extends from Fred Hutch's HIV vaccine research program.
• Office of HIV/AIDS Network Coordination (HANC)minorStrategic or Co-development PartnerHANC works with HIV/AIDS clinical trials networks funded by DAIDS/NIH to create an integrated, collaborative research structure. HVTN participates in HANC initiatives including community training materials and shared standards.
• International AIDS Vaccine Initiative (IAVI)minorStrategic or Co-development PartnerIAVI is a global nonprofit organization funded through the private sector working to speed the search for vaccines to prevent HIV/AIDS. Mentioned as a resource and related organization in HVTN's HIV Resources & Links.
• UNAIDSminorStrategic or Co-development PartnerJoint United Nations Programme on HIV/AIDS. HVTN references UNAIDS ethical guidelines and participatory practice guidelines for biomedical HIV prevention trials. UNAIDS co-published Good Participatory Practice guidelines with AVAC.
• AVAC (Global Advocacy for HIV Prevention)minorStrategic or Co-development PartnerAVAC supports HIV/AIDS research, prevention education, and advocacy. Co-published Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials with UNAIDS. AVAC's Advocates Network offers webinars and materials for community-based HIV prevention advocates, referenced by HVTN.
• AIDS Clinical Trials Group (ACTG)minorStrategic or Co-development PartnerAnother NIAID-funded HIV/AIDS clinical trials network. Listed as a related network alongside HVTN's other NIAID-funded networks.
• HIV Prevention Trials Network (HPTN)minorStrategic or Co-development PartnerAnother NIAID-funded network focused on HIV prevention research. Collaborated with HVTN on research projects such as HIV prevention combination studies published in Nature Communications.
• International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT)minorStrategic or Co-development PartnerAnother NIAID-funded clinical trials network focused on maternal, pediatric, and adolescent HIV/AIDS research. Listed as a related NIAID-funded network.
• Global HIV Vaccine EnterpriseminorStrategic or Co-development PartnerAn alliance of independent organizations dedicated to accelerating the development of a preventive HIV vaccine. Listed as a key resource and related organization by HVTN.
• Vaccine Research Center (VRC)minorStrategic or Co-development PartnerThe Dale and Betty Bumpers Vaccine Research Center at NIH is conducting cutting-edge research to develop vaccines against HIV, and has discovered new broadly neutralizing antibodies against HIV. Mentioned as a resource and partner in the HIV vaccine ecosystem.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Fred Hutchinson Cancer Center: Parent institution of HVTN and a major biomedical research organization spanning HIV, oncology, and infectious disease. Fred Hutch provides institutional infrastructure, administration, and strategic governance to HVTN's operations.

Emerging players

• Vaccine Research Center (VRC), NIAID/NIH: NIH intramural research center that discovers and develops candidate HIV vaccines and broadly neutralizing antibodies, then partners with HVTN to run clinical trials. VRC is both a research originator and a direct trial sponsor counterpart.
• International AIDS Vaccine Initiative (IAVI): Global non-profit developing HIV vaccines and broadly neutralizing antibodies, with its own clinical research programs and partnerships. IAVI complements HVTN's work in HIV vaccine development and is listed by HVTN as a key resource and related organization.

Others

• AVAC (Global Advocacy for HIV Prevention): HIV prevention advocacy organization that co-developed the Good Participatory Practice guidelines adopted by HVTN. AVAC is an ecosystem partner that supports community engagement and trial literacy alongside HVTN's research mission.
• Global HIV Vaccine Enterprise: Alliance of independent organizations dedicated to accelerating HIV vaccine development through coordination, scientific exchange, and resource mobilization. The Enterprise operates as an umbrella convener that includes HVTN and its peer networks.

Direct peers

• AIDS Clinical Trials Group (ACTG): NIAID-funded HIV/AIDS clinical trials network focused on treatment and cure research. ACTG is a sister network to HVTN, operating overlapping clinical research sites and competing for similar NIH funding and investigator talent.
• COVID-19 Prevention Network (CoVPN): NIAID-funded network built on HVTN's clinical trials infrastructure to evaluate COVID-19 vaccines and monoclonal antibodies. CoVPN leverages HVTN's site network, community engagement models, and operational expertise directly.
• International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT): NIAID-funded network conducting clinical trials in maternal, pediatric, and adolescent HIV populations. IMPAACT shares NIAID governance, site infrastructure, and statistical/data management resources with HVTN.
• HIV Prevention Trials Network (HPTN): Another NIAID/DAIDS-funded clinical trials network focused on HIV prevention research, including combination prevention and integration with HVTN. HPTN operates a similar global site infrastructure and shares investigators, participants, and funding pools with HVTN.

Regional players

• Tuberculosis Trials Consortium (TBTC): CDC-funded clinical trials network for tuberculosis research, including TB vaccine evaluation. With HVTN's 2024 expansion into TB vaccine studies, TBTC is a natural adjacent peer for shared science, sites, and competing federal funding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/helpendhiv
• Xx.com/helpendhiv

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hiv Vaccine Trials Network